Second-Line Therapy for Type 2 Diabetes Management: The Treatment/Benefit Paradox of Cardiovascular and Kidney Comorbidities-Reference-Cited by-同舟云学术

Second-Line Therapy for Type 2 Diabetes Management: The Treatment/Benefit Paradox of Cardiovascular and Kidney Comorbidities

Published:2021-08-04 Issue:10 Volume:44 Page:2302-2311
ISSN:0149-5992
Container-title:Diabetes Care
language:en
Short-container-title:Dia Care

Author:

McCoy Rozalina G.^ORCID,Van Houten Holly K.,Karaca-Mandic Pinar,Ross Joseph S.,Montori Victor M.^ORCID,Shah Nilay D.

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference39 articles.

1. Centers for Disease Control and Prevention . National Diabetes Statistics Report, 2020. Atlanta, Georgia, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2020

2. Centers for Disease Control and Prevention . Diabetes Data & Statistics. Diabetes Atlas. Division of Diabetes Translation, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Accessed 21 July 2020. Available from https://gis.cdc.gov/grasp/diabetes/DiabetesAtlas.html#

3. Risk of Cause-Specific Death in Individuals With Diabetes: A Competing Risks Analysis

4. Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death

5. Excess Mortality among Persons with Type 2 Diabetes

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of sodium‐glucose cotransporter 2 inhibitors with risk of incident dementia and all‐cause mortality in older patients with type 2 diabetes: A retrospective cohort study using the TriNetX US collaborative networks;Diabetes, Obesity and Metabolism;2024-09-09

2. Patient-important outcomes in type 2 diabetes: The paradigm of the sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists;Diabetes and Vascular Disease Research;2024-07

3. Robust inference for causal mediation analysis of recurrent event data;Statistics in Medicine;2024-05-21

4. Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile;Expert Opinion on Drug Safety;2024-05-13

5. Comparing the effectiveness and cost-effectiveness of sulfonylureas and newer diabetes drugs as second-line therapy for patients with type 2 diabetes;BMJ Open Diabetes Research & Care;2024-05